01.002 RWE APR 2022 HB C 13-04-2022

New study found higher prevalence of non-alcoholic fatty lever disease markers and cirrhosis in children

  • Non-alcoholic fatty liver disease (NAFLD) has developed into one of the most common chronic diseases, affecting children as young as two years of age, and the prevalence is continuing to increase
  • The analyses included children enrolled between August 1, 2016, and October 12th, 2020, with at least one alanine aminotransferase (ALT) measurement after enrollment
  • Researchers stratified the distribution of peak alanine aminotransferase (ALT) levels as well as the distribution of clinical characteristics by both history of a biopsy and peak serum alanine aminotransferase (ALT) level to identify comorbidities and treatment patterns in this growing
  • “There were a surprisingly high number of pediatric patients with a peak alanine aminotransferase (ALT) greater than 250 within this diverse real-world cohort,“

Eduardo Castillo-Leon

MD, Department of Pediatrics

School of Medicine, Emory University

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at